{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Cancer", "Diabetes", "Dioscin", "Metabolic disorder", "Obesity", "Osteoporosis"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "30315966", "DateCompleted": {"Year": "2019", "Month": "04", "Day": "22"}, "DateRevised": {"Year": "2019", "Month": "04", "Day": "22"}, "Article": {"ArticleDate": [{"Year": "2018", "Month": "10", "Day": "10"}], "Language": ["eng"], "ELocationID": ["10.1016/j.phrs.2018.09.022", "S1043-6618(18)31010-7"], "Journal": {"ISSN": "1096-1186", "JournalIssue": {"Volume": "137", "PubDate": {"Year": "2018", "Month": "Nov"}}, "Title": "Pharmacological research", "ISOAbbreviation": "Pharmacol Res"}, "ArticleTitle": "Dioscin: A diverse acting natural compound with therapeutic potential in metabolic diseases, cancer, inflammation and infections.", "Pagination": {"StartPage": "259", "EndPage": "269", "MedlinePgn": "259-269"}, "Abstract": {"AbstractText": ["Currently, the numbers of patients with cancer, fibrosis, diabetes, chronic kidney disease, stroke and osteoporosis are increasing fast and fast. It's critical necessary to discovery lead compounds for new drug development. Dioscin, one active compound in some medicinal plants, has anti-inflammation, immunoregulation, hypolipidemic, anti-viral, anti-fungal and anti-allergic effects. In recent years, dioscin has reached more and more attention with its potent effects to treat liver, kidney, brain, stomach and intestine damages, and metabolic diseases including diabetes, osteoporosis, obesity, hyperuricemia as well as its anti-cancer activities through adjusting multiple targets and multiple signals. Therefore, dioscin is a promising multi-target candidate to treat various diseases. This review paper summarized the progress on pharmacological activities and mechanisms of dioscin, which may provide useful data for development and exploration of this natural product in the further."], "CopyrightInformation": "Copyright \u00a9 2018 Elsevier Ltd. All rights reserved."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Pharmacy, Dalian Medical University, Western 9 Lvshunnan Road, Dalian, 116044, China."}], "LastName": "Tao", "ForeName": "Xufeng", "Initials": "X"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Pharmacy, Dalian Medical University, Western 9 Lvshunnan Road, Dalian, 116044, China."}], "LastName": "Yin", "ForeName": "Lianhong", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Pharmacy, Dalian Medical University, Western 9 Lvshunnan Road, Dalian, 116044, China."}], "LastName": "Xu", "ForeName": "Lina", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Pharmacy, Dalian Medical University, Western 9 Lvshunnan Road, Dalian, 116044, China. Electronic address: jinyongpeng2005@163.com."}], "LastName": "Peng", "ForeName": "Jinyong", "Initials": "J"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't", "Review"]}, "MedlineJournalInfo": {"Country": "Netherlands", "MedlineTA": "Pharmacol Res", "NlmUniqueID": "8907422", "ISSNLinking": "1043-6618"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Anti-Infective Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Anti-Inflammatory Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents"}, {"RegistryNumber": "3B95U4OLWV", "NameOfSubstance": "dioscin"}, {"RegistryNumber": "K49P2K8WLX", "NameOfSubstance": "Diosgenin"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Anti-Infective Agents"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Anti-Inflammatory Agents"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Antineoplastic Agents"}, {"QualifierName": ["analogs & derivatives", "therapeutic use"], "DescriptorName": "Diosgenin"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Metabolic Diseases"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Neoplasms"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2018", "Month": "7", "Day": "12"}, {"Year": "2018", "Month": "9", "Day": "19"}, {"Year": "2018", "Month": "9", "Day": "20"}, {"Year": "2018", "Month": "10", "Day": "14", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "4", "Day": "23", "Hour": "6", "Minute": "0"}, {"Year": "2018", "Month": "10", "Day": "14", "Hour": "6", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["30315966", "10.1016/j.phrs.2018.09.022", "S1043-6618(18)31010-7"]}}]}